EcoDrugPlus

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSPKIG00000025539
Gene Symbol: CFTR
3 Cross references
216 Possible Orthologues:

Dna (Cytosine-5-)-Methyltransferase 1

Ensembl ID : ENSPKIG00000010235
Gene Symbol: DNMT1
1 Cross references
77 Possible Orthologues:

Dna Topoisomerase 2-Alpha-Like

Ensembl ID : ENSPKIG00000022362
Gene Symbol: LOC111848672
3 Cross references
209 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSPKIG00000006127
Gene Symbol: TOP1
4 Cross references
198 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSPKIG00000005878
Gene Symbol: TOP1
1 Cross references
139 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSPKIG00000003370
Gene Symbol: EML4
4 Cross references
210 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSPKIG00000011776
Gene Symbol: EPHA3
2 Cross references
213 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSPKIG00000009783
Gene Symbol: EPHA3
1 Cross references
213 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSPKIG00000009355
Gene Symbol: F2RL3
4 Cross references
191 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSPKIG00000009368
Gene Symbol: F2RL3
1 Cross references
191 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSPKIG00000014856
Gene Symbol: F2RL3
3 Cross references
191 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSPKIG00000024400
Gene Symbol: F2RL3
3 Cross references
191 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).